While DYRK1A inhibitors generate human beta cell proliferation rates (labeling indices) in the 2-4% range, one can envision a need for higher rates of proliferation, especially in people with T1D who have particularly low numbers of residual beta cells. Here, DYRK1A is linked to type 1 diabetes mellitus.